Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity.
Clin Infect Dis
; 75(1): e920-e923, 2022 Aug 24.
Article
in English
| MEDLINE | ID: covidwho-2008524
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced humoral response and reactogenicity profile are described in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Findings showed that 75.0% (by Simoa assay) or 80.0% (by Roche assay) of the HSCT cohort had a positive antibody response on series completion, compared with 100% in the healthy cohort.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematopoietic Stem Cell Transplantation
/
COVID-19
/
MRNA Vaccines
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Clin Infect Dis
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
Cid
Similar
MEDLINE
...
LILACS
LIS